Last updated 2026-06-18
Portfolio
34
in our dataset
Rounds participated
47
Rounds led
11
Rounds' value
$1.2B
total disclosed, rounds participated
Stages
E Round, Pre-Seed, D Round, Seed, B Round, C Round, F Round, G Round, A Round
About
A global fund with over $1.3B AUM, with offices in Israel and Boston, USA. aMoon leverages pioneering scientific research, raw talent, and the convergence of health and technology. As Israel’s largest HealthTech-only VC fund, we partner with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare and help people live better, healthier lives.
aMoon invests across all stages of a company’s lifecycle through three investment vehicles: aMoon Velocity, our early-stage fund, aMoon Growth, our mid-late-stage fund, and aMoon Edge, our public equities fund.
We leverage our multidisciplinary team of scientists, physicians, and entrepreneurs, along with our robust network of investors and industry leaders, to build bridges between our portfolio companies and global HealthTech hubs, supporting entrepreneurs from the inception of an idea to company launch.
Portfolio · 34
Magentiq Eye
Improving Colonoscopy through AI
Lutris Pharma
Anticancer Therapy for Patients Treated with EGFR Inhibitors
MetaSight Diagnostics
Revolutionizing Liquid Biopsy
Breeoot
Personalized Healthspan Platform
Air Doctor
Marketplace Matching Travelers with Physicians Abroad
Coltac Therapeutics
Preclinical Pharmaceutical Developing Bacteria-based Synthetic Positive Selection Screening System
KAHR Medical
Fusion Proteins for Treating Cancer and Autoimmune Diseases
Lin Health
Personalized Virtual Care For Chronic Pain Relief
Ibex Medical Analytics
AI-powered Cancer Diagnostics for Pathologists
MediWound
Enzymatic Therapeutics for Non-Surgical Tissue Repair
Nectin Therapeutics
Next-generation Immunotherapy Agents
Ultima Genomics
Ultima Genomics is revolutionizing high-throughput DNA sequencing with cost-effective platforms to enable unprecedented advances in biology and improvements in human health.
Eleos Health
Automated Behavioral Care Workflow Solution
MDClone
Healthcare Data Analytics Platform
caVos Biotherapeutics
Novel Anti-cancer Drugs
Sentient Synthetics
AI-based Digital Pathology Solutions
MDSG Innovation
Medical Technology Innovation Platform
Biolojic Design
Human Antibody Therapeutics
Curesponse
Personalized Medicine for Accurate Cancer Treatment
AposHealth
Identification and Treatment of Gait-related Conditions
Vocalis Health
Voice-based Analysis and Detection of Different Health Conditions
NanoGhost
Naturally Targeted Drug Platform
Igentify
Digital Platform for Genetic Counseling and Testing
DayTwo
Precision Nutrition for Metabolic Disease
Ayala Pharmaceuticals
Targeted Therapies for People with Rare Cancers
TaGeza Biopharmaceuticals
Antibodies to Cancer Stem Cell Receptors
CTG Pharma
Enabling Therapeutic Application of Chimeric Antigen Receptor T Cells in Solid Tumors
Nobio
Advanced Antimicrobial Solutions for Medical, Dental, and Consumer Products
Zebra Medical Vision
AI-based Medical Imaging Solutions
Medial EarlySign
Early Detection of Life-threatening Conditions
Regenera Pharma
Regenerative Therapy for Neuropathies
Aummune
Individualized Immunotherapy
CartiHeal
Cell-free Cartilage Regeneration
Pharma Two B
Innovative Combinations of Previously Approved Drugs
Investment activity
4 portfolio exits on record.
Portfolio by sector
Health Tech & Life Sciences33
Industrial Technologies1
Retail Platforms1
Funds · 3
- Growth II — $340M Jul 2022
- Velocity — $114M Jan 2019
- Growth I — $750M Jan 2018
Q&A
- What is aMoon Fund's primary investment focus?
- aMoon Fund is Israel’s largest HealthTech-only VC fund, focusing on companies that leverage groundbreaking science and technology to transform healthcare.
- What is the total AUM for aMoon Fund?
- aMoon Fund has over $1.3 billion in Assets Under Management (AUM).
- Which notable exits has aMoon Fund had recently?
- aMoon Fund had a notable exit in February 2026 with the acquisition of MetaSight Diagnostics by Guardant Health for $150 million. Another significant exit was CartiHeal, acquired by Bioventus in May 2022.
- What is aMoon Fund's most recent fund close?
- aMoon Fund closed its Growth II fund in July 2022, raising $340 million.
- Can you name some of aMoon Fund's portfolio companies?
- aMoon Fund's portfolio includes companies like Ultima Genomics, which raised $604.22 million in a Seed round, and Eleos Health, which raised $128 million in a Series C round.
- What investment stages does aMoon Fund typically participate in?
- aMoon Fund invests across all stages of a company’s lifecycle, including Pre-Seed, Seed, A, B, C, D, E, F, and G Rounds.
- Who is a co-founder and managing partner at aMoon Fund?
- Yair Schindel, MD, MBA, is a Co-Founder and Managing Partner at aMoon Fund.
- What was the size of aMoon Fund's Growth I fund?
- aMoon Fund's Growth I fund, closed in January 2018, raised $750 million.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | amoon.fund/ |
|---|---|
| linkedin.com/company/27176073 | |
| YouTube | youtube.com/channel/UCi6ntDQ0otEZ8vLM3aSMIug |
Identifiers & details
| Founded | 2017 |
|---|
Radar intelligence
Web history (Wayback)
| Domain | amoon.fund |
|---|
Certificate / subdomain footprint
| Subdomains | 13 |
|---|